In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at the University of California, San Francisco, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common Spirit Health; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
In this video, the group discusses the 2025 follicular lymphoma treatment landscape.
“We don’t have good ways to risk stratify follicular lymphoma,” Dr. Nastoupil said. “[Patients] generally live a very long time, and so you’re balancing more the toxicity of the treatment with our ability to reduce the amount of disease. There’s a quality of life factor that I think we don’t always capture well in our prospective studies.”
Watch more videos from this discussion.
-
What are the therapeutic combinations in large cell lymphoma?
-
Golcadomide in the second-line setting in follicular lymphoma
-
How do you approach frontline patients in follicular lymphoma?
-
How do you approach a patient with POD24 in follicular lymphoma?
-
What are the obstacles in using CELLMoDs in DLBCL?
-
What is the 2025 treatment landscape of follicular lymphoma?
-
What are the areas of unmet needs in large cell lymphoma?
-
What is the 2025 treatment landscape in DLBCL?
This video is being brought to you by an education grant by Bristol Myers Squibb.
